|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Use of CYP1B1*3 Genotyping to Predict Survival to Docetaxel Treatment in Androgen-Independent Prostate Cancer |
Description of Invention:
Androgen-independent prostate cancer (AIPC) remains the second leading cause of cancer death in men in developed nations, and it is estimated that one in six men will be diagnosed with prostate cancer. The use of docetaxel has been shown to prolong survival rate and improve the quality of life in patients suffering from AIPC.
Scientists at NIH have identified a genetic marker called CYP1B1*3 (4326C>G; L432V) that can predict survival in patients with prostate cancer prior to treatment with docetaxel. In a study of 25 patients suffering from AIPC, patients that were homozygous or heterozygous wild-type for the 4326C>G transition had an increased mean survival time after docetaxel treatment when compared to patients carrying the homozygous variant. These patients showed a survival rate of 15.3 months compared to 7.5 months for those homozygous with the variant CYP1B1*3.
This genetic marker (CYP1B1*3) can be measured in DNA obtained from a blood sample. This technology can be potentially used as a diagnostic tool to predict the patient's propensity to respond to docetaxel treatment when being treated for AIPC.
Inventors:
William D Figg (NCI)
Patent Status:
HHS, Reference No. E-307-2005/0
EP, Application No. 06814243.9 filed 08 Sep 2006
US, Application No. 11/991,878 filed 11 Mar 2008
Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
For Licensing Information Please Contact:
Yolanda Hawkins Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hawkinsy@mail.nih.gov
Phone: 301-435-5170
Fax: 301-402-0220
Ref No: 1312
Updated: 03/2006
|
|
|
|
| |
|
|
|
|